Vis enkel innførsel

dc.contributor.authorMoore, Kristine A.
dc.contributor.authorOstrowsky, Julia T.
dc.contributor.authorKraigsley, Alison M.
dc.contributor.authorMehr, Angela J.
dc.contributor.authorBresee, Joseph S.
dc.contributor.authorFriede, Martin H.
dc.contributor.authorGellin, Bruce G.
dc.contributor.authorGolding, Josephine P.
dc.contributor.authorHart, Peter J.
dc.contributor.authorMoen, Ann
dc.contributor.authorWeller, Charlotte L.
dc.contributor.authorOsterholm, Michael T.
dc.contributor.authorAmpofo, William
dc.contributor.authorBarclay, Wendy
dc.contributor.authorCavaleri, Marco
dc.contributor.authorCohen, Cheryl
dc.contributor.authorCowling, Benjamin
dc.contributor.authorCox, Rebecca Jane
dc.contributor.authorGust, Ian
dc.contributor.authorInnis, Bruce
dc.contributor.authorKang, Gagandeep
dc.contributor.authorKatz, Jacqueline M.
dc.contributor.authorKrammer, Florian
dc.contributor.authorPitisuttithum, Punnee
dc.contributor.authorPost, Diane
dc.contributor.authorRudenko, Larisa
dc.contributor.authorSiqueira, Marilda M.
dc.contributor.authorWeir, Jerry P.
dc.date.accessioned2022-04-08T13:19:06Z
dc.date.available2022-04-08T13:19:06Z
dc.date.created2022-02-04T09:14:49Z
dc.date.issued2021
dc.identifier.issn0264-410X
dc.identifier.urihttps://hdl.handle.net/11250/2990792
dc.description.abstractImproved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleA Research and Development (R&D) roadmap for influenza vaccines: Looking toward the futureen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2021 The Authors.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.vaccine.2021.08.010
dc.identifier.cristin1997659
dc.source.journalVaccineen_US
dc.source.pagenumber6573-6584en_US
dc.identifier.citationVaccine. 2021, 39 (45), 6573-6584.en_US
dc.source.volume39en_US
dc.source.issue45en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal